Illumina Unveils Strategy to Enter Molecular Diagnostics Market | GenomeWeb

Illumina plans to enter the molecular diagnostics space by forging partnerships with customers, opening a new CLIA lab, and launching a research project to study cancer genomes, CEO Jay Flatley said during a recent presentation to investors.

Speaking at the JPMorgan Healthcare Conference in San Francisco last week, Flatley said the company will invest to improve existing sequencing technologies and develop new ones to enable it to play in the molecular diagnostics space, which he estimates to be worth $3 billion.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.